Literature DB >> 19095149

Melanoma epidemiology and trends.

Claus Garbe1, Ulrike Leiter.   

Abstract

Rising incidence rates of cutaneous melanoma have been observed during the last four decades in white populations worldwide. The cancer statistics in the United States have revealed 6 cases per 100,000 and year at the beginning of the 1970s and 18 cases per 100,000 inhabitants and year at the beginning of 2000, demonstrating a threefold increase in incidence rates. Incidence rates in central Europe increased in the same time period from 3 to 4 cases to 10 to 15 cases per 100,000 inhabitants and year, which is very similar to the increase in the United States. Cohort studies from several countries indicate that the trend of increasing incidence rates will continue in the future for at least the next 2 decades; thus, an additional doubling of incidence rates is expected. The highest incidence rates have been reported from Australia and New Zealand, from 40 to 60 cases per 100,000 inhabitants and year. Mortality rates likewise slightly increased in the United States and in Europe during the 1970s and 1980s. In the 1990 s, however, a leveling off of mortality rates was observed in many countries. Simultaneously, a clear decrease of Breslow tumor thickness was reported in the United States and European countries. This development indicates improved early recognition of cutaneous melanoma, which is presently the main factor for a more favorable prognosis.

Entities:  

Mesh:

Year:  2009        PMID: 19095149     DOI: 10.1016/j.clindermatol.2008.09.001

Source DB:  PubMed          Journal:  Clin Dermatol        ISSN: 0738-081X            Impact factor:   3.541


  149 in total

1.  Cutaneous melanoma in situ: translational evidence from a large population-based study.

Authors:  Simone Mocellin; Donato Nitti
Journal:  Oncologist       Date:  2011-05-31

2.  Enhanced postoperative lymphatic staging of malignant melanoma by endoscopically assisted iliacoinguinal dissection.

Authors:  I M Ising; A Bembenek; R Gutzmer; F Köckerling; K T Moesta
Journal:  Langenbecks Arch Surg       Date:  2011-12-24       Impact factor: 3.445

3.  Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.

Authors:  Gergo Kiszner; Barnabas Wichmann; Istvan B Nemeth; Erika Varga; Nora Meggyeshazi; Ivett Teleki; Peter Balla; Mate E Maros; Karoly Penksza; Tibor Krenacs
Journal:  Virchows Arch       Date:  2014-03-30       Impact factor: 4.064

4.  Rendomab B4, a monoclonal antibody that discriminates the human endothelin B receptor of melanoma cells and inhibits their migration.

Authors:  Aurélie Borrull; Bertrand Allard; Anne Wijkhuisen; Amaury Herbet; Patricia Lamourette; Wided Birouk; Denis Leiber; Zahra Tanfin; Frédéric Ducancel; Didier Boquet; Jean-Yves Couraud; Philippe Robin
Journal:  MAbs       Date:  2016-07-08       Impact factor: 5.857

5.  Psychological changes in melanoma patients during ipilimumab treatment compared to low-dose interferon alpha therapy-a follow-up study of first experiences.

Authors:  Péter Kovács; Gitta Pánczél; Kinga Borbola; Gabriella Juhász; Gabriella Liszkay
Journal:  Pathol Oncol Res       Date:  2014-04-27       Impact factor: 3.201

Review 6.  Emergence of zebrafish models in oncology for validating novel anticancer drug targets and nanomaterials.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Drug Discov Today       Date:  2012-08-10       Impact factor: 7.851

7.  Imaging of gastrointestinal melanoma metastases: Correlation with surgery and histopathology of resected specimen.

Authors:  Ahmed E Othman; Thomas K Eigentler; Georg Bier; Christina Pfannenberg; Hans Bösmüller; Christian Thiel; Claus Garbe; Konstantin Nikolaou; Bernhard Klumpp
Journal:  Eur Radiol       Date:  2016-10-17       Impact factor: 5.315

8.  Expression and function of CD9 in melanoma cells.

Authors:  Jun Fan; Guo-Zhang Zhu; Richard M Niles
Journal:  Mol Carcinog       Date:  2010-01       Impact factor: 4.784

9.  A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy.

Authors:  Richard F Kefford; Philip R Clingan; Benjamin Brady; Andrea Ballmer; Adele Morganti; Peter Hersey
Journal:  Mol Cancer       Date:  2010-03-30       Impact factor: 27.401

Review 10.  Role of miRNAs in the progression of malignant melanoma.

Authors:  D W Mueller; A K Bosserhoff
Journal:  Br J Cancer       Date:  2009-07-28       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.